At a glance
ClinicalIndex Comparison RecordN/ACompleted· 64 enrolled
Drug / intervention
PHIL® Liquid Embolic Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PHIL dAVF: Study of PHIL® Embolic System In The Treatment of Intracranial Dural Arteriovenous Fistulas
In Brief
A clinical study evaluating PHIL® Liquid Embolic System for Arteriovenous Dural Fistula. Completed, enrolled 64 participants across 1 site.
Detailed Summary
This study is a prospective, multicenter, single-arm study. Patients with Dural Arteriovenous Fistulas (dAVF) have a few choice for safe treatment. In this study, all patients with qualifying dAVFs will be treated with PHIL® Liquid Embolic material.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArteriovenous Dural Fistula
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedMar 2018
Enrollment StartAug 2018
Primary CompletionDec 2022
TodayJul 2026
First PostedMar 16, 2018
Enrollment StartAug 24, 2018
Primary CompletionDec 12, 2022
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 8.3 years ago
Interventions
PHIL® Liquid Embolic Systemdevice
The PHIL Embolic System is indicated in the treatment of dural arteriovenous fistulas (DAVF)